First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults

NCT06194318 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Vaccination

Interventions

BIOLOGICAL: Candidate vaccine, SCB-1019
BIOLOGICAL: placebo
BIOLOGICAL: candidate vaccine, SCB-1019T
BIOLOGICAL: AREXVY

Sponsor

Clover Biopharmaceuticals AUS Pty